Research ExplorerPublicationsModel projections on the impact of HCV treatment in the prev...

Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe

Standard

Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. / Fraser, Hannah; Martin, Natasha K; Brummer-Korvenkontio, Henrikki; Carrieri, Patrizia; Dalgard, Olav; Dillon, John; Goldberg, David; Hutchinson, Sharon; Jauffret-Roustide, Marie; Kåberg, Martin; Matser, Amy A; Matičič, Mojca; Midgard, Havard; Mravcik, Viktor; Øvrehus, Anne; Prins, Maria; Reimer, Jens; Robaeys, Geert; Schulte, Bernd; van Santen, Daniela K; Zimmermann, Ruth; Vickerman, Peter; Hickman, Matthew.

In: J HEPATOL, Vol. 68, No. 3, 03.2018, p. 402-411.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Fraser, H, Martin, NK, Brummer-Korvenkontio, H, Carrieri, P, Dalgard, O, Dillon, J, Goldberg, D, Hutchinson, S, Jauffret-Roustide, M, Kåberg, M, Matser, AA, Matičič, M, Midgard, H, Mravcik, V, Øvrehus, A, Prins, M, Reimer, J, Robaeys, G, Schulte, B, van Santen, DK, Zimmermann, R, Vickerman, P & Hickman, M 2018, 'Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe', J HEPATOL, vol. 68, no. 3, pp. 402-411. https://doi.org/10.1016/j.jhep.2017.10.010

APA

Fraser, H., Martin, N. K., Brummer-Korvenkontio, H., Carrieri, P., Dalgard, O., Dillon, J., Goldberg, D., Hutchinson, S., Jauffret-Roustide, M., Kåberg, M., Matser, A. A., Matičič, M., Midgard, H., Mravcik, V., Øvrehus, A., Prins, M., Reimer, J., Robaeys, G., Schulte, B., ... Hickman, M. (2018). Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J HEPATOL, 68(3), 402-411. https://doi.org/10.1016/j.jhep.2017.10.010

Vancouver

Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J HEPATOL. 2018 Mar;68(3):402-411. https://doi.org/10.1016/j.jhep.2017.10.010

Bibtex

@article{853a69c586fe4826bcbd93db86a19f5b,
title = "Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe",
abstract = "BACKGROUND & AIMS: Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of current and scaled-up HCV treatment with and without scaling up opioid substitution therapy (OST) and needle and syringe programmes (NSPs) across Europe over the next 10 years.METHODS: We collected data on PWID HCV treatment rates, PWID prevalence, HCV prevalence, OST, and NSP coverage from 11 European settings. We parameterised an HCV transmission model to setting-specific data that project chronic HCV prevalence and incidence among PWID.RESULTS: At baseline, chronic HCV prevalence varied from <25% (Slovenia/Czech Republic) to >55% (Finland/Sweden), and <2% (Amsterdam/Hamburg/Norway/Denmark/Sweden) to 5% (Slovenia/Czech Republic) of chronically infected PWID were treated annually. The current treatment rates using new direct-acting antivirals (DAAs) may achieve observable reductions in chronic prevalence (38-63%) in 10 years in Czech Republic, Slovenia, and Amsterdam. Doubling the HCV treatment rates will reduce prevalence in other sites (12-24%; Belgium/Denmark/Hamburg/Norway/Scotland), but is unlikely to reduce prevalence in Sweden and Finland. Scaling-up OST and NSP to 80% coverage with current treatment rates using DAAs could achieve observable reductions in HCV prevalence (18-79%) in all sites. Using DAAs, Slovenia and Amsterdam are projected to reduce incidence to 2 per 100 person years or less in 10 years. Moderate to substantial increases in the current treatment rates are required to achieve the same impact elsewhere, from 1.4 to 3 times (Czech Republic and France), 5-17 times (France, Scotland, Hamburg, Norway, Denmark, Belgium, and Sweden), to 200 times (Finland). Scaling-up OST and NSP coverage to 80% in all sites reduces treatment scale-up needed by 20-80%.CONCLUSIONS: The scale-up of HCV treatment and other interventions is needed in most settings to minimise HCV transmission among PWID in Europe.LAY SUMMARY: Measuring the amount of HCV in the population of PWID is uncertain. To reduce HCV infection to minimal levels in Europe will require scale-up of both HCV treatment and other interventions that reduce injecting risk (especially OST and provision of sterile injecting equipment).",
keywords = "Journal Article",
author = "Hannah Fraser and Martin, {Natasha K} and Henrikki Brummer-Korvenkontio and Patrizia Carrieri and Olav Dalgard and John Dillon and David Goldberg and Sharon Hutchinson and Marie Jauffret-Roustide and Martin K{\aa}berg and Matser, {Amy A} and Mojca Mati{\v c}i{\v c} and Havard Midgard and Viktor Mravcik and Anne {\O}vrehus and Maria Prins and Jens Reimer and Geert Robaeys and Bernd Schulte and {van Santen}, {Daniela K} and Ruth Zimmermann and Peter Vickerman and Matthew Hickman",
note = "Copyright {\textcopyright} 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.",
year = "2018",
month = mar,
doi = "10.1016/j.jhep.2017.10.010",
language = "English",
volume = "68",
pages = "402--411",
journal = "J HEPATOL",
issn = "0168-8278",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe

AU - Fraser, Hannah

AU - Martin, Natasha K

AU - Brummer-Korvenkontio, Henrikki

AU - Carrieri, Patrizia

AU - Dalgard, Olav

AU - Dillon, John

AU - Goldberg, David

AU - Hutchinson, Sharon

AU - Jauffret-Roustide, Marie

AU - Kåberg, Martin

AU - Matser, Amy A

AU - Matičič, Mojca

AU - Midgard, Havard

AU - Mravcik, Viktor

AU - Øvrehus, Anne

AU - Prins, Maria

AU - Reimer, Jens

AU - Robaeys, Geert

AU - Schulte, Bernd

AU - van Santen, Daniela K

AU - Zimmermann, Ruth

AU - Vickerman, Peter

AU - Hickman, Matthew

N1 - Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

PY - 2018/3

Y1 - 2018/3

N2 - BACKGROUND & AIMS: Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of current and scaled-up HCV treatment with and without scaling up opioid substitution therapy (OST) and needle and syringe programmes (NSPs) across Europe over the next 10 years.METHODS: We collected data on PWID HCV treatment rates, PWID prevalence, HCV prevalence, OST, and NSP coverage from 11 European settings. We parameterised an HCV transmission model to setting-specific data that project chronic HCV prevalence and incidence among PWID.RESULTS: At baseline, chronic HCV prevalence varied from <25% (Slovenia/Czech Republic) to >55% (Finland/Sweden), and <2% (Amsterdam/Hamburg/Norway/Denmark/Sweden) to 5% (Slovenia/Czech Republic) of chronically infected PWID were treated annually. The current treatment rates using new direct-acting antivirals (DAAs) may achieve observable reductions in chronic prevalence (38-63%) in 10 years in Czech Republic, Slovenia, and Amsterdam. Doubling the HCV treatment rates will reduce prevalence in other sites (12-24%; Belgium/Denmark/Hamburg/Norway/Scotland), but is unlikely to reduce prevalence in Sweden and Finland. Scaling-up OST and NSP to 80% coverage with current treatment rates using DAAs could achieve observable reductions in HCV prevalence (18-79%) in all sites. Using DAAs, Slovenia and Amsterdam are projected to reduce incidence to 2 per 100 person years or less in 10 years. Moderate to substantial increases in the current treatment rates are required to achieve the same impact elsewhere, from 1.4 to 3 times (Czech Republic and France), 5-17 times (France, Scotland, Hamburg, Norway, Denmark, Belgium, and Sweden), to 200 times (Finland). Scaling-up OST and NSP coverage to 80% in all sites reduces treatment scale-up needed by 20-80%.CONCLUSIONS: The scale-up of HCV treatment and other interventions is needed in most settings to minimise HCV transmission among PWID in Europe.LAY SUMMARY: Measuring the amount of HCV in the population of PWID is uncertain. To reduce HCV infection to minimal levels in Europe will require scale-up of both HCV treatment and other interventions that reduce injecting risk (especially OST and provision of sterile injecting equipment).

AB - BACKGROUND & AIMS: Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of current and scaled-up HCV treatment with and without scaling up opioid substitution therapy (OST) and needle and syringe programmes (NSPs) across Europe over the next 10 years.METHODS: We collected data on PWID HCV treatment rates, PWID prevalence, HCV prevalence, OST, and NSP coverage from 11 European settings. We parameterised an HCV transmission model to setting-specific data that project chronic HCV prevalence and incidence among PWID.RESULTS: At baseline, chronic HCV prevalence varied from <25% (Slovenia/Czech Republic) to >55% (Finland/Sweden), and <2% (Amsterdam/Hamburg/Norway/Denmark/Sweden) to 5% (Slovenia/Czech Republic) of chronically infected PWID were treated annually. The current treatment rates using new direct-acting antivirals (DAAs) may achieve observable reductions in chronic prevalence (38-63%) in 10 years in Czech Republic, Slovenia, and Amsterdam. Doubling the HCV treatment rates will reduce prevalence in other sites (12-24%; Belgium/Denmark/Hamburg/Norway/Scotland), but is unlikely to reduce prevalence in Sweden and Finland. Scaling-up OST and NSP to 80% coverage with current treatment rates using DAAs could achieve observable reductions in HCV prevalence (18-79%) in all sites. Using DAAs, Slovenia and Amsterdam are projected to reduce incidence to 2 per 100 person years or less in 10 years. Moderate to substantial increases in the current treatment rates are required to achieve the same impact elsewhere, from 1.4 to 3 times (Czech Republic and France), 5-17 times (France, Scotland, Hamburg, Norway, Denmark, Belgium, and Sweden), to 200 times (Finland). Scaling-up OST and NSP coverage to 80% in all sites reduces treatment scale-up needed by 20-80%.CONCLUSIONS: The scale-up of HCV treatment and other interventions is needed in most settings to minimise HCV transmission among PWID in Europe.LAY SUMMARY: Measuring the amount of HCV in the population of PWID is uncertain. To reduce HCV infection to minimal levels in Europe will require scale-up of both HCV treatment and other interventions that reduce injecting risk (especially OST and provision of sterile injecting equipment).

KW - Journal Article

U2 - 10.1016/j.jhep.2017.10.010

DO - 10.1016/j.jhep.2017.10.010

M3 - SCORING: Journal article

C2 - 29080808

VL - 68

SP - 402

EP - 411

JO - J HEPATOL

JF - J HEPATOL

SN - 0168-8278

IS - 3

ER -